Black Diamond Therapeutics Inc (BDTX)

[dcaf7]

I think, recent SP decline is related to three factors. 1. World Conference of Lung Cancer in September where several studies on drugs targeting EGFR mutations in lung cancer were presented, including 4th generation TKIs. It showed that market is relatively crowded. 2. Outcome of Janssen Landmark Phase 3 MARIPOSA Study where RYBREVANT plus lazertinib beat Osimertinib in 1st line EGFRmut NSCLC. It should affect BDTX strategy for 1535 development. Placing it post Osimertinib might became not so relevant. 3. CEO employment termination without cause.
Guess, all eyes are on data readout in GBM this quarter.